Central Bank of Nigeria to Attend Remittance Optimization Forum in Houston

In collaboration with NIBSS, Nigerian banks, and IMTOs, the CBN seeks to deepen engagement with the Nigerian diaspora community HOUSTON, Oct. 19, 2024 — The Central Bank of Nigeria (CBN), in collaboration with the Nigeria Inter-Bank Settlement System (NIBSS), major Nigerian banking institutions, and International Money Transfer Operators (IMTOs), will participate in a pivotal forum titled Optimizing Remittances to Nigeria: A Vision for the Future” in Houston, Texas, on October 20, 2024. This important event…

Xiao-I Corp. Investors with Losses May Be Eligible to Join Class Action Lawsuit, Says Bronstein, Gewirtz & Grossman LLC

 NEW YORK, Oct. 20, 2024 — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, is informing investors that a class action lawsuit has been filed against Xiao-I Corp. (“Xiao-I” or “the Company”) (NASDAQ: AIXI) and some of its executives. Class Definition The lawsuit seeks to recover…

Jiangxi Intangible Cultural Heritage Enters a New Era

NANCHANG, China, Oct. 20, 2024 — A report from Jiangxi International Communication Center(JXICC):   Intangible cultural heritage represents the legacy of ancient skills and holds endless possibilities for the future. How does Jiangxi's Intangible Cultural Heritage interact with AI? Technology empowers traditional culture, breathing life into these skills. Let's witness…

Moomoo Releases Redesigned Desktop Platform

JERSEY CITY, N.J., Oct. 18, 2024 — Moomoo has recently launched its redesigned desktop platform to better serve U.S. retail investors and help them unlock their trading potential. The newly developed, client-driven platform provides customizable multi-monitor layouts with advanced features specifically tailored for investors, including powerful charting and analytical tools.…

MicuRx Pharmaceuticals Highlights Pipeline Progress for MRX-5 and MRX-8 at BIO Investor Forum

SAN FRANCISCO, Oct. 18, 2024 — Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of the company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These development programs offer new potentials for the future treatment of Nontuberculous Mycobacterial (NTM) pulmonary diseases and Pseudomonas…

Accord Healthcare’s Biosimilar to Stelara® Receives Positive CHMP Opinion

Accord announces that the CHMP has issued a positive opinion for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immunology conditions. The approval of Imuldosa® further enhances Accord Healthcare’s biosimilar portfolio and strengthens Accord’s Autoimmune Franchise building on existing leading brands. Imuldosa® will be the 5th biosimilar for…

Foreign Journalists and Bloggers Explore the “Pearl of Western Jiangxi”

PINGXIANG, China, Oct. 19, 2024 — A report from Jiangxi International Communication Center(JXICC): Recently, a group of foreign journalists and bloggers from seven countries including the UK, Japan, South Korea, and Indonesia visited Pingxiang in Jiangxi Province. They explored Pingxiang's cultural heritage and witnessed the stunning natural beauty of Wugong Mountain. Pingxiang,…

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

Luxembourg, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE")…